# Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles

> **NCT01406600** · NA · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 70 (estimated)

## Conditions studied

- in Vitro Fertilization
- Poor Responder

## Interventions

- **DRUG:** recombinant hCG (Ovidrel®)

## Key facts

- **NCT ID:** NCT01406600
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-09
- **Primary completion:** 2013-11
- **Final completion:** 2013-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2013-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01406600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01406600, "Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT01406600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*